# Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

> **NCT04353973** · NA · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 256 (actual)

## Conditions studied

- Cancer

## Interventions

- **OTHER:** Pre-Test Intervention
- **OTHER:** Standard of Care
- **OTHER:** Post-Test Intervention

## Key facts

- **NCT ID:** NCT04353973
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-17
- **Primary completion:** 2024-08-15
- **Final completion:** 2025-02-13
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04353973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04353973, "Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04353973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*